Be‐Sheng Kuo

443 citations
29 papers · 318 indexed · h-index 10
Topics
Drug Transport and Resistance Mechanisms (6 papers)Pharmacogenetics and Drug Metabolism (6 papers)HER2/EGFR in Cancer Research (5 papers)

In The Last Decade

Be‐Sheng Kuo

26 papers receiving 296 citations

Peers

Be‐Sheng Kuo
Comparison fields: 5 of 75
  • Physiology 98
  • Molecular Biology 91
  • Pharmacology 60
  • Oncology 43
  • Surgery 42
Replace Julia M. Ford with:
Julia M. Ford United Kingdom
Xinnan Li China
Vikash Sinha United States
Bing Bai China
Xuelian Hu China
Jessica Mancuso United States
Holger Fuchs Germany
Ian Gurrell United Kingdom
Elizabeth Sanchez‐Rangel United States
Catherine Centeno Switzerland
Be‐Sheng Kuo relative to Julia M. Ford United Kingdom Julia M. Ford's profile →
Citations per field
00.5×8.4×
Julia M. Ford · 1×
Citations per year

Countries citing papers authored by Be‐Sheng Kuo

Since Specialization
Citations

This map shows the geographic impact of Be‐Sheng Kuo's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Be‐Sheng Kuo with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Be‐Sheng Kuo more than expected).

Fields of papers citing papers by Be‐Sheng Kuo

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Be‐Sheng Kuo. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Be‐Sheng Kuo. The network helps show where Be‐Sheng Kuo may publish in the future.

Co-authorship network of co-authors of Be‐Sheng Kuo

This figure shows the co-authorship network connecting the top 25 collaborators of Be‐Sheng Kuo. A scholar is included among the top collaborators of Be‐Sheng Kuo based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Be‐Sheng Kuo. Be‐Sheng Kuo is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
#WorkIndexed citations
1 8
2 9
3
Syntheses and biological activities of chiral piperidines-tachykinin NK3 antagonists.
3
4 40
5 8
6 10
7 13
8 3
9 1
10 4
11 0
12 5
13 1
14 7
15 1
16 3
17 20
18 11
19 15
20 6

About Be‐Sheng Kuo

Be‐Sheng Kuo is a scholar working on Pharmacology, Filtration and Separation and Oncology, having authored 29 papers that have together received 318 indexed citations. Recurring topics across this work include Drug Transport and Resistance Mechanisms (6 papers), Pharmacogenetics and Drug Metabolism (6 papers) and HER2/EGFR in Cancer Research (5 papers). The work is most often cited by research in Biological Psychiatry (21 citations), Neurology (35 citations) and Physiology (98 citations). Be‐Sheng Kuo has collaborated with scholars based in United States, United Kingdom and Czechia. Frequent co-authors include D. Scott Wright, T D Bjornsson, Kin‐Kai Hwang, Gil Korner, Chang Yi Wang, Chih‐Chieh Yu, Feng Lin, Pei‐Ning Wang, Kesheng Zhao and Thorir D. Bjornsson. Their work appears in journals such as Nucleic Acids Research, Journal of Clinical Investigation and Analytical Biochemistry.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026